Surasak Phuphanich, MD

Surasak Phuphanich, MD

Pavilion (AHSP)
127 S San Vicente Blvd
Ste A6600
Los AngelesCA
90048

Phone:

310-423-8100

Fax:

310-967-8696

Hunt Cancer Center
3285 Skypark Dr
TorranceCA
90505

Phone:

310-750-3312

Fax:

310-517-0629

Torrance Memorial Medical Center - Neurosciences Institute
23560 Crenshaw Blvd
Ste 101
TorranceCA
90505

Phone:

310-517-7022

Fax:

310-539-1050

Surasak Phuphanich, MD

  • Neurology
  • Neuro-Oncology, Brain/Spine Tumor

The clinical and research interests of Surasak Phuphanich, MD, are drug delivery with nano-particle through blood brain barrier (BBB) and drug discovery with focus on promising new Immunomodulation and targeted therapeutic agents. For example, PD-1/PDL-1 Antibody, M-Tor inhibitor, PI3 Kinase, Hedge-hog pathway, IDH1, EGFR-TKI, VEGFR, and immunotherapy with vaccine and stem cell for different specific cancer cell targets including correlation with proteinomic, genomic profile in order to avoid major side effects and maintain high quality of life in this group of patients with the ultimate goal of offering personalized Neuro-Oncology medicine for every patient with brain cancer.

  • Medical School: Mahidol University, 1975
  • Residency: Mahidol University, 1977
  • Internship: Saint Francis Hospital of Evanston, 1978
  • Residency: University of Illinois Hospital & Health Sciences System, 1981
  • Fellowship: University of California, San Francisco Medical Center, 1983

View CV as a PDF

  • Golden Hippocampus Teaching Award, 2016
  • Best Doctors, Best Doctors, Inc., 2011-14
  • Top's American Physicians Award, Consumer Research Council, 2009-12
  • Patient’s Choice Award, MDx Medical, Inc., 2008-12
  • America's Top Doctors for Cancer, Castle Connelly Medical Ltd., 2007-15

Click here for a list of peer-reviewed publications.

  • Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuño MA, Richardson JE, Fan X, Ji J, Chu RM, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2013;62(1):125-135.
  • Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, et al. A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. Clin Cancer Res. 2019 Oct 1;25(19):5799-5807.
  • El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich S, et al. The Current State of Molecular Testing in the Treatment of Patients with Solid Tumors. CA Cancer J Clin. 2019 Jul;69(4):305-343.

English / Spanish / Thai

Make an Appointment

Call

1-800-CEDARS-1

(1-800-233-2771)

Available 24 Hours A Day

or

Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.